Journal article
Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma
M Waibel, G Gregory, J Shortt, RW Johnstone
Current Opinion in Hematology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
Abstract
PURPOSE OF REVIEW: The identification of oncogenic 'driver' mutations and activated survival pathways in selected aggressive B-cell malignancies directs the development of novel adjunctive therapies using targeted small molecule inhibitors. With a focus on diffuse large B-cell lymphoma 'not otherwise specified', Hodgkin lymphoma and childhood B-cell precursor acute lymphoblastic leukemia, this review will provide an up-to-date account of the current literature on the development of new molecularly targeted treatment modalities for aggressive B-cell malignancies. RECENT FINDINGS: Subclassification of B-cell malignancies depending on their particular genetic 'driver' lesions and transcriptiona..
View full abstractGrants
Funding Acknowledgements
M.W. was supported by a project grant from the National Health and Medical Research Council (NHMRC) of Australia. J.S. was supported by the Leukemia Foundation of Australia (LFA) and the Cooperative Research Centre for Biomedical Imaging Development and is currently supported by a project grant from the NHMRC. G.G. is supported by the LFA and R.W.J. is a Principal Research Fellow of the NHMRC and supported by NHMRC Program and Project Grants and the Cancer Council Victoria.